Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 2:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–22 of 22 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Enterotoxigenic Escherichia Coli Infection Clear all
Completed Phase 2 Interventional Accepts healthy volunteers

ETEC Logistics Trial (TREK)

NCT00516659
View directory record Official record
Conditions
Diarrhea
Interventions
Heat-Labile Enterotoxin of Escherichia coli (LT), Placebo
Biological
Lead sponsor
Intercell USA, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
201 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
13
States / cities
Long Beach, California • Chicago, Illinois • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2012 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A

NCT02773446
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
47 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study in Healthy Adults Challenged With Enterotoxigenic E. Coli, of the Safety, Tolerability and Anti-Diarrheal Activity of VENBETA6890, an Orally Administered, Human Monoclonal IgA

NCT06896136
View directory record Official record
Conditions
Diarrhea Infectious
Interventions
VENBETA6890, Placebo
Drug
Lead sponsor
Mark Klempner
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Clinical Study to Assess the Efficacy of IMM-124E (Travelan®) in a Controlled Human Infection Model

NCT05933525
View directory record Official record
Conditions
Diarrhea, Travelers Diarrhea, Infectious Diarrhea
Interventions
Travelan, Placebo
Biological · Other
Lead sponsor
Immuron Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Efficacy of B7A BSIgG Against E. Coli Strain B7A Challenge

NCT03040687
View directory record Official record
Conditions
Healthy Volunteer
Interventions
Anti CS6 BSIgG product (Lot PD1601105CS), Anti B7A BSIgG product (Lot PD1601132ET), Bovine Immunoglobin Negative Control (Lot PD161071NC), B7A- CS6-expressing ETEC challenge strain
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 50 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 13, 2019 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy of Bovine Milk Immunoglobulin Against CS17 and CsbD

NCT00524004
View directory record Official record
Conditions
Travelers' Diarrhea
Interventions
Anti-CsbD Bovine IgG, Placebo, Anti-CS17 Bovin IgG
Biological · Other
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Jun 10, 2026, 2:05 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Double-Blind Placebo-Control Dose Escalating Study to Evaluate the Safety and Immunogenicity of dmLT by Oral, Sublingual and Intradermal Vaccination in Adults Residing in an Endemic Area

NCT03548064
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli, Immunisation
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Challenge Study of an ETEC Vaccine

NCT01922856
View directory record Official record
Conditions
Enteritis; Escherichia Coli, Enterotoxigenic
Interventions
LTR192G with dscCfaE, No Intervention
Biological · Other
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 50 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ACE527 Safety and Immunogenicity Study

NCT00901654
View directory record Official record
Conditions
Enterotoxigenic E. Coli (ETEC) Infection
Interventions
ACE527 vaccine, Placebo vaccine
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 28, 2010 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity of Peru-15-pCTB in Healthy Adult Subjects

NCT00654108
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Ciprofloxacin, Peru-15-pCTB, Sodium bicarbonate/Ascorbic Acid/Aspartame Buffer
Drug · Biological · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
62 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 28, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety Study of Chimeric Vaccine to Prevent ETEC Diarrhea

NCT01644565
View directory record Official record
Conditions
Escherichia Coli Infection
Interventions
Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5, Recombinant fimbrial adhesin dscCfaE, Modified E. coli heat labile enterotoxin LTR192G
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 45 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of Sublingual dmLT for ETEC

NCT02052934
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2019 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

Prevention of Travelers' Diarrhea in Subjects Traveling Outside the U.S.

NCT00328380
View directory record Official record
Conditions
Diarrhea
Interventions
Rifaximin
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
3
States / cities
South Miami, Florida • Houston, Texas • La Porte, Texas
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant

NCT03922061
View directory record Official record
Conditions
Polio
Interventions
dmLT, fIPV
Biological
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated Aug 4, 2020 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-finding Study of WS6788A, DS37-4 and H10407 Enterotoxigenic Escherichia Coli (ETEC) Challenge Strains

NCT00198796
View directory record Official record
Conditions
Diarrhea
Interventions
H10407
Biological
Lead sponsor
Johns Hopkins Bloomberg School of Public Health
Other
Eligibility
18 Years to 45 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 10, 2017 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of dmLT ID Vaccination in Healthy Adults

NCT02531685
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Placebo, Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 25, 2020 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Safety and Efficacy Study of a Vaccine Against Enterotoxigenic Escherichia Coli (ETEC) to Prevent Moderate to Severe Diarrhea

NCT01060748
View directory record Official record
Conditions
Diarrhea
Interventions
ACE527, Placebo
Biological
Lead sponsor
TD Vaccines A/S
Industry
Eligibility
18 Years to 50 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 6, 2011 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of ETEC Vaccine

NCT01147445
View directory record Official record
Conditions
Gastroenteritis Escherichia Coli
Interventions
Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) Vaccine
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dose Escalating Study of a Prototype CS6 Subunit Vaccine With a Modified Heat-labile Enterotoxin From Enterotoxigenic Escherichia Coli (ETEC)

NCT03404674
View directory record Official record
Conditions
Diarrhea
Interventions
CssBA, dmLT
Biological
Lead sponsor
PATH
Other
Eligibility
18 Years to 45 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study Confirming A Human Challenge Model and Investigating The Safety Of VLA1701

NCT03576183
View directory record Official record
Conditions
Enterotoxigenic Escherichia Coli Infection, Diarrhea
Interventions
VLA1701, Placebo, Challenge Strain
Biological · Other
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years to 49 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 22, 2021 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Shigella CVD 31000: Study of Responses With Shigella-ETEC Vaccine Strain CVD 1208S-122

NCT04634513
View directory record Official record
Conditions
Shigella Infection, Enterotoxigenic Escherichia Coli Infection
Interventions
strain CVD 1208S-122, Placebo
Biological · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 49 Years
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jun 10, 2026, 2:05 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Efficacy Study of IM Administered CssBA+dmLT Against Moderate-severe Diarrhea in Human Infection Model With ETEC Strain B7A in Healthy Adults

NCT06692907
View directory record Official record
Conditions
Escherichia Infection
Interventions
B7A (ETEC challenge strain), CssBA, dmLT, Placebo
Other · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 49 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Baltimore, Maryland • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Jun 10, 2026, 2:05 PM EDT